Louisiana advocate Kat MacFarlane speak about the importance of physician/patient relationships, the promise of biosimilars when made available transparently, and why she is testifying about biosimilar substitution in the legislature.
Oregon Advocate Anna Meyer speaks on an interview for KODL for Biosimilars
Would you want your pharmacist to tell you and your doctor if they substituted your biologic medication with a similar, but not identical drug? Of course you would. But as biosimilars — a less expensive mimic of Biologics — are introduced on the U.S. market, individual states are deciding how and when they can be […]
GHLF released the findings of a national survey of stabilized patients that explored their perspectives on switching prescribed biological medicines. The survey, “Patient Perspectives on Medication Switching for Non- Medical Reasons,” found 98 percent of the 177 eligible respondents said insurance companies and pharmacists should not switch effective therapies without patient and physician notification.
The clock starts ticking as soon as a patient experiences symptoms of an adverse reaction. When the worst happens, we want our healthcare team to have the maximum information available to them in order to find the cause quickly and accurately. That is why the Global Healthy Living Foundation (GHLF) and its members fully support the FDA’s decision to incorporate a distinguishable name for the first approved biosimilar – filgrasim-sndz. There has been a lot of debate about […]